Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Clinical Trial to Evaluate the Efficacy of a Dolutegravir Monotherapy (Tivicay) Versus the Maintenance of a Successful Triple Therapy Using Abacavir + Lamivudine + Dolutegravir (Triumeq) in HIV-1- Infected Patients

Trial Profile

Randomized Clinical Trial to Evaluate the Efficacy of a Dolutegravir Monotherapy (Tivicay) Versus the Maintenance of a Successful Triple Therapy Using Abacavir + Lamivudine + Dolutegravir (Triumeq) in HIV-1- Infected Patients

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir (Primary) ; Abacavir/dolutegravir/lamivudine
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms MONCAY
  • Most Recent Events

    • 11 Jul 2019 Results of pooled analysis of data from MONCAY and TRULIGHT trials assessing proportion of participants who had no detectable HIV in genital fluids were published in the Clinical Infectious Diseases.
    • 02 Jan 2019 Primary endpoint (Viral Load) has been met, according to the results published in the Clinical Infectious Diseases.
    • 02 Jan 2019 Results published in the Clinical Infectious Diseases
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top